Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Gloria Julia Nazco"'
Autor:
Marta Llanos Muñoz, Ruth Ramos Díaz, José A. Pérez, Sara García Gil, María Micaela Viña Romero, Fernando Gutiérrez Nicolás, Gloria Julia Nazco Casariego, Braulio Martin Calero
Publikováno v:
Medicina Clínica (English Edition). 151:425-430
Background and objectives Evaluate the relationship between the presence of polymorphisms in genes involved in the pharmacodynamics of irinotecan (UGT1A, SLCO1B1, ABCB1 and ABCC2) and the safety of irinotecan in the treatment of metastatic colorectal
Autor:
Javier González, Maria Queralt Gorgas, Concepción Violán, Albert Roso-Llorach, Marisa Baré, Susana Herranz, Rosa Jordana, Sara Ortonobes, Daniel Sevilla, Candelaria Martín, Marina Lleal, Núria Solà, Núria Molist, Mariona Espauella, Oscar Mascaró, Elisabet de Jaime, Olivia Ferrandez, Maria Sala, Miguel Ángel Márquez, Marta Arellano, Carlos Clemente, Olga Sabartés, Núria Carballo, Marta de Antonio, Rafael Estrada, Maria Olatz Ibarra, Gloria Julia Nazco, Rubén Hernández, Pere Roura-Poch
Publikováno v:
BMJ Open
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
BMJ Open, Vol 11, Iss 11 (2021)
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
BMJ Open, Vol 11, Iss 11 (2021)
ObjectivesTo estimate the frequency of chronic conditions and geriatric syndromes in older patients admitted to hospital because of an exacerbation of their chronic conditions, and to identify multimorbidity clusters in these patients.DesignMulticent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11bfdd92d8ea5d27f153239ede5f0e1c
http://hdl.handle.net/10230/53762
http://hdl.handle.net/10230/53762
Autor:
Isaac Ceballos Lenza, Ruth Ramos Díaz, Matías Llabres Martinez, Jonathan González García, José Norberto Batista López, Gloria Julia Nazco Casariego, Fernando Gutiérrez Nicolás
Publikováno v:
Annals of Pharmacotherapy. 51:976-980
Background: Plasma concentrations of trastuzumab min) of 20 µg/mL after first drug administration, established as therapeutically effective in clinical trials. The secondary objective was to identify the physiological and anthropometric characterist